Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVRC biomarker study of mexiletine and muscle excitability
NL-OMON49444Not yet recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of fresolimumab in myasthenia gravis (MG) (3 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Relative refractory period, Early supernormality and 8 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
fresolimumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON49444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49444.